Date: 2012-06-18
Type of information: R&D agreement
Compound: novel disulfide rich peptides (DRPs)
Company: Zealand Pharma (Denmark) Protagonist Therapeutics (USA)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: Zealand Pharma, a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, has signed a collaboration agreement with Protagonist Therapeutics, Inc., a privately-owned US incorporated biotechnology company. Under the agreement, Zealand Pharma and Protagonist will join forces to identify, optimize and develop novel disulfide rich peptides (DRPs) with the therapeutic potential to offer better treatment for patients in defined, non-disclosed disease areas.
Protagonist brings to the collaboration a validated and proprietary technology platform for the discovery and optimization of novel DRPs (disulfide-rich peptides). Besides potent biological activity, DRPs are characterized by inherent stabilizing properties which lead to improved pharmacokinetic profiles. Zealand Pharma has identified the disease targets for the peptide drug discovery activities covered by the collaboration and will be responsible for preclinical and clinical drug development of DRPs, discovered under the collaboration.
Financial terms: Zealand Pharma will finance all activities under the agreement and will retain all rights to novel DRP drug candidates stemming from the collaboration. Protagonist will receive an undisclosed upfront payment and will be entitled to receive additional payments dependent upon the successful achievement of pre-defined discovery and development milestones as well as on Zealand Pharma\'s product sales and revenues from partnering agreements. In addition, Protagonist has been granted an option to co-finance Zealand Pharma’s development of DRP drug candidates.
Latest news:
